Areas of activity
Development of patient-derived preclinical tumor models, immuno-oncology with focus on autologous T cells, macrophages and dendritic cells
Stages of career
09/2018 - Present Doktorandin, Tumorbiologie, NMI
08/2017 - 10/2017 Research Scholar, California Pacific Medical Center Research Institute, San Francisco
05/2016 - 09/2016 Research Intern, Tumorbiologie, NMI
2014 - 2018 Molecular Cell Biology and Immunology (Master of Science), Eberhard Karls Universität Tübingen
2012 - 2014 Biology (Bachelor of Science), Universität Hohenheim
Nicole Anderle
Scientist Tumor Biology
M.Sc.Molekulare Zellbiologie und Immunologie
Publications
-
Argyrin F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental GliomaWalter B, Canjuga D, Yüz S, Ghosh M, Bozko P, Przystal J, Govindarajan P, Anderle N, Keller AL, Tatagiba M, Schenke-Layland K, Rammensee HG, Stevanovic S, Malek N P, Schmees C, and TabatabaiGDOI: 10.1002/adtp.202100078
-
Generation and characterization of the human induced pluripotent stem cell line NMIi010-A from peripheral blood mononuclear cells of a healthy 49–year old male individualKeller AK, Binner A, Breitmeyer R, Vogel S, Anderle N, Rothbauer U, Schenke-Layland K, Schmees CStem Cell Research Volume 54, July 2021, 102427, https://doi.org/10.1016/j.scr.2021.102427
-
Generation and characterization of the human induced pluripotent stem cell line NMIi010-A from peripheral blood mononuclear cells of a healthy 49–year old male individualKeller AL, Binner A, Breitmeyer R, Vogel S, Anderle N, Rothbauer U, Schenke-Layland K, Schmees Ctem Cell Res. 2021 Jul;54:102427. doi: 10.1016/j.scr.2021.102427. Epub 2021 Jun 11. PMID: 34139596.
-
Targeting CSF1R Alone or in Combination with PD1 in Experimental GliomaPrzystal JM, Becker H, Canjuga C, Tsiami F, Anderle N, Keller A, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai GCancers 2021, 13(10), 2400; https://doi.org/10.3390/cancers13102400